Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

Enanta Pharmaceuticals, Inc (ENTA)

Pharmaceutical Preparations

https://www.enanta.com

Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

500 ARSENAL STREET
WATERTOWN, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

03/21/2013

Market Cap

259,348,464

Shares Outstanding

21,060,000

Weighted SO

21,058,925

Total Employees

N/A

Upcoming Earnings

11/18/2024

Similar Tickers

GLUE --.--%

DSGN --.--%

HOWL --.--%

IKNA --.--%

STOK --.--%

CRNX --.--%

INBX --.--%

MRUS --.--%

LYEL --.--%

Beta

0.6030

Last Div

0.0000

Range

8.08-17.8

Chg

-0.0200

Avg Vol

187003

Mkt Cap

259348464

Exch

NASDAQ

Country

US

Phone

617 607 0800

DCF Diff

21.0349

DCF

-8.8549

Div Yield

0.0000

P/S

3.6041

EV Multiple

-4.0102

P/FV

1.7409

Div Yield %

0.0000

P/E

-2.2479

PEG

0.2827

Payout

0.0000

Current Ratio

4.9215

Quick Ratio

4.9215

Cash Ratio

0.6248

DSO

206.0911

DIO

0.0001

Op Cycle

206.0912

DPO

1542.5079

CCC

-1336.4167

Gross Margin

0.9649

Op Margin

-1.7074

Pretax Margin

-1.6415

Net Margin

-1.6027

Eff Tax Rate

0.0236

ROA

-0.2892

ROE

-0.6375

ROCE

-0.3607

NI/EBT

0.9764

EBT/EBIT

0.9614

EBIT/Rev

-1.7074

Debt Ratio

0.4464

D/E

1.1956

LT Debt/Cap

0.4904

Total Debt/Cap

0.5445

Int Coverage

-19.2461

CF/Debt

-0.5053

Equity Multi

2.6782

Rec Turnover

1.7711

Pay Turnover

0.2366

Inv Turnover

999999.9999

FA Turnover

1.0860

Asset Turnover

0.1804

OCF/Share

-4.2477

FCF/Share

-4.7371

Cash/Share

10.8920

OCF/Sales

-1.2502

FCF/OCF

1.1152

CF Coverage

-0.5053

ST Coverage

-2.5907

CapEx Coverage

-8.6798

Div&CapEx Cov

-8.6798

P/BV

1.7409

P/B

1.7409

P/S

3.6041

P/E

-2.2479

P/FCF

-2.5849

P/OCF

-2.8816

P/CF

-2.8816

PEG

0.2827

P/S

3.6041

EV Multiple

-4.0102

P/FV

1.7409

DPS

0.0000

Latest Headlines (EST)

Zacks Investment Research Jan 05, 03:09 Strength Seen in Enanta Pharmaceuticals (ENTA): Can Its 13.8% Jump Turn into More Strength?

Revenue Product Segmentation